Mind Medicine Australia FREE Webinar: The Potential of Psychedelic Drugs to Treat Serious Mental Illness with Dr Guy Goodwin (UK)

Don’t miss out - Get your tickets early!

Join this FREE WEBINAR presented by Dr Guy Goodwin (UK)

TOPIC: The Potential of Psychedelic Drugs to Treat Serious Mental Illness

Psychedelic treatments are rapidly moving from research into clinical practice, signaling a potential transformation in how we treat serious mental health conditions. Through this webinar, participants will gain an understanding of: 

• Psychedelic pharmacology and clinical applications surrounding psychedelic treatments

• The emerging profile of Compass' lead compound COMP360 

• The unmet needs of two conditions in major need of innovation: treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD)

• The evolving models of care during administration of psychedelic treatment and the nuances between administration with and without therapy

EVENT DETAILS

• DATE: 21st October 2026

• TIME: 5:55pm (AEDT) for 6:00pm start, finishing at 7:15pm

• DURATION: 75 minutes (incl Q&A)

• LOCATION: Online - a link will be emailed to you with the viewing details

A replay of the event will be made available on our YouTube channel.

ABOUT THE PRESENTER

Dr Guy Goodwin (UK)

Chief Medical Officer, Compass Pathways

Guy completed his medical degree and DPhil in physiology at the University of Oxford and, following training in psychiatry, worked as Clinical Scientist at the MRC Brain Metabolism Unit in Edinburgh for 10 years. He moved back to Oxford as head of the department of psychiatry and subsequently as a senior research fellow. His work has always included care of outpatients along with a primary commitment to research. He is a Fellow of the American College of Neuropsychopharmacology, and has previously held the position of President of the British Association for Psychopharmacology, President of the European College of Neuropsychopharmacology (ECNP), and Senior Investigator on the faculty of UK National Institute for Health Research (NIHR). He is a Thomson Reuters highly cited researcher (top 1% in field).

His research interests have been focused on the treatment of mood disorder and, increasingly, the potential to improve treatment using new technology and new drugs, notably psychedelics. He was part of the team that developed Compass Pathways’ phase IIb clinical trial and acted initially as its coordinating principal investigator. 

---

MEDICINAL PSYCHEDELIC TREATMENTS

Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.

The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.

SUPPORT PSYCHEDELIC RESEARCH AND THERAPY DEVELOPMENT

Your donation to Mind Medicine Australia will help us accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support. Please click here to make a tax-deductible donation.

DISCLAIMER

Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms i.e. Facebook, Instagram or zoom private and public chat forms during the webinar. Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters. Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses.